Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

Nine-year-old Leo has been under the care of Sheffield Children’s Hospital all his life, after he had an infection when he ...

Researchers at the University of California San Diego say the decline is real, documenting a continuing drop in cigarette smoking across the United States, led largely by young adults. Their findings ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

On Saturday, May 3, more than 150 firefighters from five departments across the Atlanta area will join the American Lung Association to raise awareness and critical funds for people living with lung ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

A 23-year-old patient from Pakistan undergoing treatment in a corporate hospital on ECMO support for 70 days passed away.

Stricter air-quality rules, pushed through in the last days of the Biden administration, face an uncertain future under a ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Most new emphysema is propagated in high mechanically affected lung regions rather than in lung areas with small airways disease.

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...